enVVeno Medical Corporation (NASDAQ: NVNO) announced on August 4, 2026, that a peer-reviewed health economic study published in the Journal of Vascular Surgery: Venous and Lymphatic Disorders confirms its venous valve replacement therapy is economically dominant compared to standard conservative management. The study demonstrates that treating severe deep venous reflux with the company’s technology generates significant healthcare savings and improved clinical outcomes, providing critical evidence to support future coverage determinations and reimbursement policies for its next-generation non-surgical device, enVVe.
The research, titled "Cost-effectiveness of a prosthetic venous valve versus compression therapies and wound care for treatment of infra-inguinal deep vein reflux," analyzed the economic impact of VenoValve, enVVeno's first-generation surgical technology. The analysis concluded that the therapy is economically dominant versus compression therapy and wound care over a five-year period. Key findings include average healthcare savings of more than $32,000 per patient and the avoidance of approximately 2.2 venous ulcers per patient. The treatment was projected to become cost-effective by approximately Year 2, generating net healthcare savings between Years 2 and 3.
Economic Impact and Clinical Outcomes
The research highlights substantial benefits across both financial and clinical metrics. Beyond the per-patient savings, the study estimated that broader adoption of effective venous valve replacement therapy could translate into approximately $5.9 billion in annual healthcare savings. This figure underscores the significant burden of chronic deep venous insufficiency and the commercial opportunity for therapies addressing the underlying cause of the disease.
| Metric |
Value |
| Projected healthcare savings per patient (5-year) |
More than $32,000 |
| Venous ulcers avoided per patient |
Approximately 2.2 |
| Cost savings per rVCSS point improvement |
Approximately $4,100 |
| Estimated annual industry savings |
Approximately $5.9 billion |
The revised Venous Clinical Severity Score (rVCSS), a validated clinical tool used to evaluate disease severity and treatment response in patients with chronic venous disease, showed strong correlation with economic benefits. The study projected approximately $4,100 in cost savings for each rVCSS point of clinical improvement. Additionally, the therapy demonstrated improved quality-adjusted life years (QALYs) and lower overall healthcare costs compared to current conservative management strategies.
What the Numbers Show
The data indicates a rapid return on investment for healthcare systems adopting this therapy. With treatment becoming cost-effective by Year 2 and generating net savings thereafter, the financial burden shifts significantly away from long-term wound care and ulcer management. The dominance of the therapy over standard compression treatments suggests that early intervention with valve replacement could disrupt the traditional high-cost trajectory of managing deep venous disease.
These findings are particularly relevant for enVVeno's next-generation enVVe device, which is currently being studied in the TAVVE pivotal trial. While the published analysis focused on the first-generation VenoValve technology, the results provide important health economic support for the therapeutic potential of the newer non-surgical platform. Robert Berman, Chief Executive Officer of enVVeno Medical, stated that this independent scientific validation provides compelling evidence for the enVVe system compared to standard of care treatments. The company intends to use this evidence to engage with payers and policymakers regarding coverage and reimbursement decisions once clinical data from the TAVVE trial is available.
19
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
